AbbVie Inc. (ABBV)

AbbVie Inc. operates in the Pharmaceutical Preparations industry (SIC 2834), developing, manufacturing, and commercializing medicines for immunology, oncology, neuroscience, eye care, and aesthetics. Its major products include Skyrizi, Rinvoq, Botox, Vraylar, and Venclexta. Headquartered in North Chicago, Illinois, United States. Incorporated in Delaware. Fiscal year ends December 31. Filing category: Large accelerated filer.

TickerABBV
CompanyAbbVie Inc.
ExchangeNYSE
HeadquartersNORTH CHICAGO, IL

Income statement — period ending 2026-06-30

Comprehensive Income (Loss), Net of Tax, Attributable to Parent$3,608,000,000
Cost of Goods and Services Sold$4,291,000,000
Earnings Per Share, Basic2 USD/shares
Earnings Per Share, Diluted2 USD/shares
Gross Profit (derived)$12,699,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest$4,278,000,000
Income Tax Expense (Benefit)$662,000,000
Interest Expense$746,000,000
Investment Income, Interest$67,000,000
Net Income (Loss) Attributable to Parent$3,613,000,000
Net Income (Loss) Attributable to Noncontrolling Interest$3,000,000
Net Income (Loss) Available to Common Stockholders, Basic$3,601,000,000
Operating Income (Loss)$6,432,000,000
Other Nonoperating Income (Expense)-$1,475,000,000
Other Operating Income (Expense), Net$0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest$3,616,000,000
Revenues$16,990,000,000
Selling, General and Administrative Expense$3,632,000,000
Share-based Payment Arrangement, Noncash Expense$610,000,000
Weighted Average Number of Shares Outstanding, Diluted1,771,000,000 shares
Weighted Average Number of Shares Outstanding, Basic1,769,000,000 shares

Sourced from SEC EDGAR/XBRL filings via StockSpectro.

View full interactive research on StockSpectro